Expression of a dominant negative estrogen receptor alpha variant in transgenic mice accelerates uterine cancer induced by the potent estrogen diethylstilbestrol.
暂无分享,去创建一个
K. Korach | J. F. Couse | R. Newbold | W. Jefferson | E. Goulding | B. Bullock | Katherine J. Hamilton | Katie M. Gallagher | S. L. Rea | Vicki L. Davis | Edward M. Eddy
[1] M. Villegas,et al. Inhibition of Neu-Induced Mammary Carcinogenesis in Transgenic Mice Expressing ERΔ3, a Dominant Negative Estrogen Receptor α Variant , 2012, Hormones and Cancer.
[2] O. Ortmann,et al. Identification of novel transcript variants of estrogen receptor α, β and progesterone receptor gene in human endometrium , 2010, Endocrine.
[3] J. Kim,et al. Role of Progesterone in Endometrial Cancer , 2010, Seminars in reproductive medicine.
[4] Leping Li,et al. Estrogen-mediated Regulation of Igf1 Transcription and Uterine Growth Involves Direct Binding of Estrogen Receptor α to Estrogen-responsive Elements* , 2009, The Journal of Biological Chemistry.
[5] D. Vergara,et al. Hormonal carcinogenesis and socio‐biological development factors in endometrial cancer: A clinical review , 2008, Acta obstetricia et gynecologica Scandinavica.
[6] Stephen Safe,et al. Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. , 2008, Journal of molecular endocrinology.
[7] G. Chen,et al. Estrogen and its receptors in cancer , 2008, Medicinal research reviews.
[8] K. Kim,et al. Minireview: estrogen receptor-mediated rapid signaling. , 2006, Endocrinology.
[9] A. Nardulli,et al. Cell- and Ligand-specific Regulation of Promoters Containing Activator Protein-1 and Sp1 Sites by Estrogen Receptors α and β* , 2005, Journal of Biological Chemistry.
[10] S. Fuqua,et al. Estrogen receptor mutations in human disease. , 2004, Endocrine reviews.
[11] Jean‐Luc C. Mougeot,et al. Estrogen receptor–α messenger RNA variants that lack exon 5 or exon 7 are coexpressed with wild-type form in human endometrium during all phases of the menstrual cycle , 2004 .
[12] R. Clarke,et al. Expression of an estrogen receptor variant lacking exon 3 in derivatives of MCF-7 cells with acquired estrogen independence or tamoxifen resistance. , 2004, Journal of molecular endocrinology.
[13] A. Nardulli,et al. Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site. , 2004, Molecular endocrinology.
[14] J. Gierthy,et al. Phenotypic changes in MCF-7 cells during prolonged exposure to tamoxifen , 2003, Molecular and Cellular Endocrinology.
[15] K. Korach,et al. Characterization of the hypothalamic-pituitary-gonadal axis in estrogen receptor (ER) Null mice reveals hypergonadism and endocrine sex reversal in females lacking ERalpha but not ERbeta. , 2003, Molecular endocrinology.
[16] Brad Saville,et al. Domains of Estrogen Receptor α (ERα) Required for ERα/Sp1-Mediated Activation of GC-Rich Promoters by Estrogens and Antiestrogens in Breast Cancer Cells , 2003 .
[17] A. Nardulli,et al. Estrogen Receptor α and Activating Protein-1 Mediate Estrogen Responsiveness of the Progesterone Receptor Gene in MCF-7 Breast Cancer Cells , 2002 .
[18] A. Parfitt,et al. Reversal of Bone Loss in Mice by Nongenotropic Signaling of Sex Steroids , 2002, Science.
[19] E. J. Lee,et al. An estrogen receptor (ER)alpha deoxyribonucleic acid-binding domain knock-in mutation provides evidence for nonclassical ER pathway signaling in vivo. , 2002, Molecular endocrinology.
[20] K. Korach,et al. An estrogen receptor repressor induces cataract formation in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[21] K. Korach,et al. Estrogen Receptor-α Knockout Mice Exhibit Resistance to the Developmental Effects of Neonatal Diethylstilbestrol Exposure on the Female Reproductive Tract , 2001 .
[22] A. Nardulli,et al. Sp1 binding sites and an estrogen response element half-site are involved in regulation of the human progesterone receptor A promoter. , 2000, Molecular endocrinology.
[23] A. Bollig,et al. An estrogen receptor-alpha splicing variant mediates both positive and negative effects on gene transcription. , 2000, Molecular endocrinology.
[24] G. Horvath,et al. Exon deletions and variants of human estrogen receptor mRNA in endometrial hyperplasia and adenocarcinoma. , 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
[25] T. Maudelonde,et al. Expression of oestrogen receptor-alpha splicing variants and oestrogen receptor-beta in endometrium of infertile patients. , 1998, Molecular human reproduction.
[26] L. Ossowski,et al. Loss of an Estrogen Receptor Isoform (ERαΔ3) in Breast Cancer and the Consequences of Its Reexpression: Interference with Estrogen-Stimulated Properties of Malignant Transformation , 1997 .
[27] K. Korach,et al. Tissue Distribution and Quantitative Analysis of Estrogen Receptor-α (ERα) and Estrogen Receptor-β (ERβ) Messenger Ribonucleic Acid in the Wild-Type and ERα-Knockout Mouse. , 1997, Endocrinology.
[28] J. Gustafsson,et al. Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor alpha. , 1997, Molecular endocrinology.
[29] E. Resnick,et al. Specific modulation of estrogen receptor mRNA isoforms in rat pituitary throughout the estrous cycle and in response to steroid hormones , 1997, Molecular and Cellular Endocrinology.
[30] K. Korach,et al. Accelerated onset of uterine tumors in transgenic mice with aberrant expression of the estrogen receptor after neonatal exposure to diethylstilbestrol , 1997, Molecular carcinogenesis.
[31] S. Shousha,et al. Presence of exon 5-deleted oestrogen receptor in human breast cancer: functional analysis and clinical significance. , 1997, British Journal of Cancer.
[32] A. Klibanski,et al. Tumor-specific expression of alternatively spliced estrogen receptor messenger ribonucleic acid variants in human pituitary adenomas. , 1997, The Journal of clinical endocrinology and metabolism.
[33] A. Jazaeri,et al. Estrogen receptor mRNA splice variants in pre- and postmenopausal human endometrium and endometrial carcinoma. , 1997, Gynecologic oncology.
[34] R. Derynck,et al. Expression of a dominant-negative type II transforming growth factor β (TGF-β) receptor in the epidermis of transgenic mice blocks TGF-β-mediated growth inhibition , 1997 .
[35] F. Walsh,et al. Expression of a Dominant Negative FGF Receptor Inhibits Axonal Growth and FGF Receptor Phosphorylation Stimulated by CAMs , 1997, Neuron.
[36] J. Miyazaki,et al. Myeloid differentiation is impaired in transgenic mice with targeted expression of a dominant negative form of retinoid X receptor β , 1997, British journal of haematology.
[37] W. Park,et al. Identification of a variant estrogen receptor lacking exon 4 and its coexpression with wild-type estrogen receptor in ovarian carcinomas. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[38] M D Shelby,et al. Assessing environmental chemicals for estrogenicity using a combination of in vitro and in vivo assays. , 1996, Environmental Health Perspectives.
[39] R. Maronpot,et al. Spontaneous Lesions in Aging FVB/N Mice , 1996, Toxicologic pathology.
[40] K. Korach,et al. Physiological coupling of growth factor and steroid receptor signaling pathways: estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[41] K. Korach,et al. Analysis of transcription and estrogen insensitivity in the female mouse after targeted disruption of the estrogen receptor gene. , 1995, Molecular endocrinology.
[42] A. Ullrich,et al. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. , 1995, The EMBO journal.
[43] J. Kato,et al. Presence of alternatively spliced-estrogen receptor mRNA variants in normal human uterine endometrium and endometrial cancer. , 1995, Endocrine journal.
[44] K. Korach,et al. An improved method of genomic DNA extraction for screening transgenic mice. , 1994, BioTechniques.
[45] K. Korach,et al. Aberrant reproductive phenotypes evident in transgenic mice expressing the wild-type mouse estrogen receptor. , 1994, Endocrinology.
[46] K. Korach,et al. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[47] Y. Wang,et al. Identification of a dominant negative form of the human estrogen receptor. , 1991, Molecular endocrinology.
[48] R. Jaenisch,et al. A generic intron increases gene expression in transgenic mice , 1991, Molecular and cellular biology.
[49] T. Roderick,et al. FVB/N: an inbred mouse strain preferable for transgenic analyses. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[50] F. Gannon,et al. Evidence for a previously unidentified upstream exon in the human oestrogen receptor gene. , 1991, Journal of molecular endocrinology.
[51] R. Palmiter,et al. Heterologous introns can enhance expression of transgenes in mice. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[52] J. McLachlan,et al. Uterine adenocarcinoma in mice following developmental treatment with estrogens: a model for hormonal carcinogenesis. , 1990, Cancer research.
[53] K. Korach,et al. Developmental pattern of estrogen receptor expression in female mouse genital tracts. , 1989, Endocrinology.
[54] P. Chambon,et al. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer , 1988, Cell.
[55] K. Korach,et al. Immunodetection of estrogen receptor in epithelial and stromal tissues of neonatal mouse uterus. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[56] J. Ham,et al. Structural organization and expression of the mouse estrogen receptor. , 1987, Molecular endocrinology.
[57] G. Hager,et al. Modulation of enhancer activity by the hormone responsive regulatory element from mouse mammary tumor virus. , 1984, The EMBO journal.
[58] B. A. Harris,et al. Plasmids for the cloning and expression of full-length double-stranded cDNAs under control of the SV40 early or late gene promoter. , 1983, Nucleic acids research.
[59] A. Herbst,et al. DES-related female genital changes. , 1982, Seminars in oncology.
[60] W. Rutter,et al. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.
[61] David Bouchez,et al. Manipulating the Mouse Embryo , 2007 .
[62] C. Teng,et al. Lactoferrin gene expression and regulation: an overview. , 2002, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[63] J. Gustafsson,et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. , 1997, Endocrinology.
[64] Newbold Rr,et al. Cellular and molecular mechanisms of cancers of the uterus in animals. , 1996 .
[65] M. Tsai,et al. The Nuclear Hormone Receptor Superfamily: Structure and Function , 1996 .
[66] Newbold Rr,et al. Transplacental hormonal carcinogenesis: diethylstilbestrol as an example. , 1996 .
[67] T. Brennan,et al. Clear cell adenocarcinoma of the vagina and cervix: incidence, undetected disease, and diethylstilbestrol. , 1988, Journal of clinical epidemiology.